Literature DB >> 16797382

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

Martin MacKinnon1, Sabin Shurraw, Ayub Akbari, Greg A Knoll, James Jaffey, Heather D Clark.   

Abstract

Blockade of the renin-angiotensin system with either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) was shown to decrease urinary protein excretion and slow the progression of both diabetic and nondiabetic proteinuric renal disease. The safety and efficacy of combined ACE-inhibitor and ARB therapy is not well established. We conducted a systematic review and meta-analysis of randomized trials evaluating the combination of an ACE inhibitor and an ARB in patients with chronic proteinuric renal disease. Twenty-one randomized controlled studies (n = 654 patients) were identified using MEDLINE, EMBASE, and Cochrane Central databases. Five trials had a parallel-group design and 16 trials used a crossover design. Combination therapy with an ACE inhibitor and an ARB resulted in a small, but significant, increase in serum potassium levels (weighted mean difference, 0.11 mEq/L [0.11 mmol/L]; 95% confidence interval [CI], 0.05 to 0.17) and a nonsignificant decrease in glomerular filtration rate (weighted mean difference, 1.4 mL/min [0.02 mL/s]; 95% CI, -2.6 to 0.2). Addition of an ARB resulted in a further decrease in proteinuria (weighted mean difference, 440 mg/d; 95% CI, 289 to 591) compared with an ACE inhibitor alone. This effect was observed in patients with diabetic (210 mg/d; 95% CI, 84 to 336) and nondiabetic (582 mg/d; 95% CI, 371 to 793) renal disease. In conclusion, the combination of ACE-inhibitor and ARB therapy in patients with chronic proteinuric renal disease is safe, without clinically meaningful changes in serum potassium levels or glomerular filtration rates. Combination therapy also was associated with a significant decrease in proteinuria, at least in the short term. Additional trials with longer follow-up are needed to determine whether the decrease in proteinuria will result in significant preservation of renal function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16797382     DOI: 10.1053/j.ajkd.2006.04.077

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  49 in total

1.  Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Kaleab Z Abebe; Arlene B Chapman; Robert W Schrier; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Charity G Moore; Ronald D Perrone
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

2.  Angiotensin and renal disease: the jury is still out.

Authors:  Saul Blecker; Nirav R Shah
Journal:  Am J Kidney Dis       Date:  2007-03       Impact factor: 8.860

3.  Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland.

Authors:  Wan A H Wan Md Adnan; Nur L Zaharan; Kathleen Bennett; Catherine A Wall
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 4.  Dihydropyridine calcium channel antagonists in the management of hypertension.

Authors:  Benjamin J Epstein; Katherine Vogel; Biff F Palmer
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease.

Authors:  Stuart L Linas
Journal:  Clin J Am Soc Nephrol       Date:  2008-01       Impact factor: 8.237

6.  Waiting for combined treatment with RAS inhibitors in children with primary glomerulonephritis.

Authors:  Marco Zaffanello
Journal:  Pediatr Nephrol       Date:  2008-08-08       Impact factor: 3.714

7.  Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.

Authors:  Masayoshi Okumi; Noritaka Kawada; Naotsugu Ichimaru; Harumi Kitamura; Toyofumi Abe; Ryoichi Imamura; Yasuyuki Kojima; Yukito Kokado; Yoshitaka Isaka; Hiromi Rakugi; Norio Nonomura; Toshiki Moriyama; Shiro Takahara
Journal:  Clin Exp Nephrol       Date:  2011-08-05       Impact factor: 2.801

8.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

9.  Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.

Authors:  María Gracia Caletti; Alejandro Balestracci; Mabel Missoni; Clarisa Vezzani
Journal:  Pediatr Nephrol       Date:  2012-12-20       Impact factor: 3.714

Review 10.  [Hypertension and the kidney].

Authors:  Katharina Hohenstein; Bruno Watschinger
Journal:  Wien Med Wochenschr       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.